Asterias Biotherapeutics

6300 Dumbarton Circle
United States


Show jobs for this employer

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. is a biotechnology company pioneering the field of regenerative medicine. The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of neurology and oncology. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury.

Stock Symbol: AST

Stock Exchange: NYSE


In 2016, Lucas Lindner was in a car accident that left him paralyzed from the neck down. Lindner was enrolled in a clinical trial at the Medical College of Wisconsin and was operated on at Froedtert Hospital in Milwaukee. He received 10 million AST-OPC1 cells injected into the injured area of his spinal cord. These cells have helped Lindner regain function in his arms, hands and fingers. He was the third patient in the world to receive the cells developed by Asterias Biotherapeutics. This is his story.

137 articles about Asterias Biotherapeutics